Novartis AG - Change Receivables

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Change-Receivables" stands at -0.868 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

Novartis AG's third quarter result of 0.18 Billion USD for the item "Change Receivables" represents an increase of 207.78 percent compared to it's second quarter result.

Also, Novartis AG's third quarter result of 0.18 Billion USD for the item "Change Receivables" represents a decrease of -45.12 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of -0.868 Billion USD for the item "Change Receivables" represents a decrease of -20.56 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 0.4672 Billion United States Dollars compared to the value the year prior.
The 1 year change is 0.4672 Billion United States Dollars.
The 3 year change is -0.262 Billion United States Dollars.
The 5 year change is -0.299 Billion United States Dollars.
The 10 year change is -0.501 Billion United States Dollars.

The Serie's long term average value is -0.837 Billion United States Dollars. It's latest available value, on 09/30/2025, is -0.0306 Billion United States Dollars lower, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 12/31/2019, to it's latest available value, on 09/30/2025, is +3.05 Billion.
The Serie's change in United States Dollars from it's maximum value, on 12/31/2020, to it's latest available value, on 09/30/2025, is -1.42 Billion.